AzTrials
AzTrials

Airway ManagementOPTIMISE-2NCT05967507

Laryngoscopy for Neonatal and Infant Airway Management wIth Supplemental Oxygen at Different Flow Rates (OPTIMISE-2)

A study testing Low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope and High-flow nasal supplemental oxygen (Fisher & Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope in people with Airway Management, run by Thomas Riva at 11 sites in 7 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to investigate the optimal oxygen flow rate needed during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) using Miller-blade or Macintosh-blade size No. 0 or No. 1 in the operating room or intensive care unit. Read more about this study

Who is it for?
Ages Up to 52 weeks
Conditions the study is for
Airway Management
What is being tested?
Low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope and High-flow nasal supplemental oxygen (Fisher & Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,192 participants
Where
11 sitesin 7 countries
Study dates
1 Dec 2023to Sep 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 52 weeks
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Pediatric patients requiring oral or nasal tracheal intubation for elective, semi-elective, or urgent surgical and non-surgical indications.
  • Neonates and infants up to 52 weeks postconceptual age, with legal guardians providing written informed consent before the intervention

Who cannot join

  • Prediction of difficult intubation upon physical examination or previous history of difficult intubation, mandating a technique different than direct laryngoscopy to secure the airway;
  • Congenital heart disease demanding FiO2 < 1.0
  • Cardiopulmonary collapse requiring advanced life support
  • Intubation for emergency surgical and non-surgical indications.

Trial locations and contacts

11 sites in 7 countries. Contact the study team or a site near you to ask about taking part.

Alexander Fuchs, MD contact

+41 31 632 52 01

alexander.fuchs@insel.ch

Thomas Riva, MD contact

+41 31 632 17 09

thomasriva@me.com

11 sites in 7 countries

Switzerland4 sites, 3 recruiting
  • Kantonsspital Aarau, KSA

    Aarau, Canton of Aargau

    Lorenz Theiler, Prof, +41 062 838 41 41, lorenz.theiler@ksa.ch

    Lorenz Theiler, MD

    Recruiting
  • Inselspital

    Bern, 3010

    Alexander Fuchs, MD, 41316321709, alexander.fuchs@insel.ch

    Thomas Riva, MD, 41316321709, thomas.riva@insel.ch

    Recruiting
  • CHUV Centre Hospitalier Universitaire Vaudois

    Lausanne, 1011

    Active, not recruiting
  • Luzerner Kantonsspital

    Lucerne, Canton of Lucerne, 6004

    Martin Hoelzle, MD, +41 41 205 61 11, martin.hoelzle@luks.ch

    Martin Hoelzle, MD

    Recruiting

Other trials in Switzerland

Canada2 sites, 2 recruiting
  • Dept. Anesthesia, Montreal Children's Hospital, McGill University Health Centre

    Montreal

    Thomas Engelhardt, Prof., thomas.engelhardt@mcgill.ca

    Thomas Engelhardt, MD

    Recruiting
  • Dept. Anesthesia, The Hospital for Sick Children

    Toronto, Ontario

    Clyde Matava, Prof., clyde.matava@sickkids.ca

    Clyde Matava, MD

    Recruiting

Other trials in Canada

United States1 site, 1 recruiting
  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104

    Annery Garcia Marcinkiewicz, Professor, 800-879-2467, garciamara@chop.edu

    Annery Garcia Marcinkiewicz, MD

    Recruiting

Other trials in United States

Australia1 site, 1 recruiting
  • Perth Children's Hospital

    Perth, Western Australia, 6009

    Britta von Ungern Sternberg, Prof, +08 6456 2222, britta.regli-vonungern@uwa.edu.au

    Britta von Ungern Sternberg, MD

    Recruiting

Other trials in Australia

Brazil1 site, 1 recruiting
  • Hospital Municipal Infantil Menino Jesus, Servicos Medicos de Anestesia

    São Paulo, São Paulo

    Vinicius Quintao, Prof, +55 11 3016-0500, vinicius.quintao@hc.fm.usp.br

    Vinicius Quintao, MD

    Recruiting

Other trials in Brazil

Germany1 site, 1 recruiting
  • Department of Cardiac Anesthesiology and Intensive Care Medicine, Charité Universitätsmedizin

    Berlin

    Maren Kleine-Brueggeney, Prof. Dr., maren.kleine-brueggeney@dhzc-charite.de

    Maren Kleine-Brueggeney, MD

    Recruiting

Other trials in Germany

Italy1 site, 1 recruiting
  • IRCCS Istituto Giannina Gaslini

    Genova, 16147

    Nicola Disma, Prof, +39 010 56361, nicoladisma@gaslini.org

    Nicola Disma, MD

    Recruiting

Other trials in Italy

About this study

Official title: Laryngoscopy for Neonatal and Infant Airway Management wIth Supplemental Oxygen at Different Flow Rates (OPTIMISE-2): a Multi-center, Non-inferiority, Prospective Randomized Controlled Trial

This study aims to investigate the optimal oxygen flow rate needed during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) using Miller-blade or Macintosh-blade size No. 0 or No. 1 in the operating room or intensive care unit. The investigators hypothesize that the difference between low-flow and high-flow supplemental oxygen is negligible.

Read the detailed description

Eligible children will be prepared for intubation according to the local SOPs of the pediatric anesthesia departments. Mandatory monitoring will consist of: SpO2, HR, NIBP.

Induction of anesthesia: If feasible, all children included in this protocol will be pre-oxygenated before induction of anesthesia for one minute through face-mask with FiO2 1.0 and flow rates of 6-10L/min. The induction of anesthesia for tracheal intubation will be performed using a combination of sedative/hypnotic drugs, opioids and non-depolarizing muscle relaxant.

The following medications will be mandatory as per protocol:

  • A neuromuscular blocking agent (NMBA): Rocuronium 0.5-1 mg/kg, Cis-Atracurium 0.2-0.5 mg/kg, Atracurium 0,5 mg/kg, Vecuronium 0.1 mg/kg, Mivacurium 0.2 - 0.3 mg/kg or Succinylcholine 2 mg/kg.
  • One or more of the following hypnotic agents (Thiopentone 4-7 mg/kg, Ketamine 0.5-2 mg/kg, Propofol 1-4 mg/kg, Midazolam 0.5-1 mg/kg, Sevoflurane up to 8%).
  • An opioid drug and anticholinergic can be chosen and administered at the discretion of the anesthetist in charge.

Before intubation: After induction of anesthesia and the administration of a NMBA, bag-mask ventilation with FiO2 1.0 (flow rates of 6-10 L/min) will be performed for 60 seconds until apnea sets in. After induction all patients will be paralyzed to facilitate airway management. Full neuromuscular blockade will be assessed by train-of-four (TOF) monitoring. Thereafter oxygen administration, laryngoscopy and tracheal intubation are performed.

During intubation: The administration of oxygen during intubation is mandatory for every study participant and is randomized as follows:

Low-flow Oxygen Group: For orally intubated children, the administration of low-flow oxygen (0.2 L/kg/min FiO2 1.0) takes place via conventional nasal cannula (Intersurgical, Wokingham, UK). For nasally intubated children, the administration of low-flow oxygen (0.2 L/kg/min FiO2 1.0) takes place via a nasal oxygen sponge cannula (Vygon, Ecouen, France) adapted to the dimension of nare. After administration of low-flow oxygen laryngoscopy and tracheal intubation are performed.

High-Flow Oxygen Group (control-group): For all orally intubated children, the administration of high-flow oxygen (2 L/kg/min FiO2 1.0) takes place via nasal cannula with the Optiflow (Fisher \& Paykel Healthcare, Auckland, New Zealand). For nasally intubated children, the administration of low-flow oxygen (2 L/kg/min FiO2 1.0) takes place via the anaesthesia circuit through the tracheal tube placed in the nose. After administration of high-flow oxygen laryngoscopy and tracheal intubation are performed.

For a premature neonate < 1kg an uncuffed tube ID 2.5 will be used. For premature babies and newborn between 1kg and 3.0 kg an uncuffed tube ID 3.0 will be used. For babies > 3.0 kg - 8 months a cuffed tube ID 3.0 or an uncuffed tube 3.5 will be used. For infants 8 months - 12 months a cuffed tube ID 3.5 or an uncuffed tube 4.0 will be used. Based on the group of randomization, the child will receive supplemental oxygen low-flow via a conventional nasal cannula vs high-flow with the Optiflow (Fisher \& Paykel Healthcare, Auckland, New Zealand).

Miller-blade or Macintosh-blade size No. 0 will be used for children < 1 kg. In cases of unexpected difficult intubation, the difficult airway algorithm (18) will be followed. After the first unsuccessful intubation attempt with the randomized flowrate, the investigators encourage to perform a second attempt with the same rate but based on the clinical judgment the intubating physician can proceed to an attempt with the same technique, or change the flow rate, blade size or the type of laryngoscope. A maximum of 4 intubation attempts in total will be performed. The last intubation attempt must be performed by the most experienced physician in the room. Additional devices like stylet, bougie, etc., can be used at any stage of the intubation process. If the intubation remains unsuccessful the difficult airway algorithm will be followed (Appendix) and a supraglottic airway - SGA will be inserted.

Being tested
Low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope, High-flow nasal supplemental oxygen (Fisher & Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscopeDevice

    0.2 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.

  • High-flow nasal supplemental oxygen (Fisher & Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscopeDevice

    2 L/kg/min FiO2 1.0 high-flow nasal supplemental oxygen (Fisher \& Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.

Study groups in NCT05967507
Study groupRoleWhat they receive
Intervention groupExperimental0.2 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with conventional nasal cannula during tracheal intubation performed with the C-MAC videolaryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
Receives: Device: Low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope
Control groupActive comparator2 L/kg/min FiO2 1.0 high-flow nasal supplemental oxygen with the Optiflow (Fisher \& Paykel Healthcare, Auckland, New Zealand) during tracheal intubation performed with the C-MAC videolaryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
Receives: Device: High-flow nasal supplemental oxygen (Fisher & Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. First attempt success rate

    The primary study outcome is to evaluate the first attempt success rate of oral and nasal tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with supplemental oxygen with low-flow vs high flow among neonates and infants up to 52 weeks postconceptual age. A successful tracheal intubation (ETI) attempt is defined as successful placement of a tracheal tube in the trachea, confirmed by visualization of the tube passing the vocal cords, a waveform capnography suggesting correct ETT placement and auscultation of breath sounds in the lungs.

    Measured: 15 minutes

Secondary outcomes (10)
  1. Occurrence of severe desaturation

    Occurrence and duration of moderate and severe desaturation (SpO2 < 10% and SpO2 < 20% from baseline), with or without bradycardia, during intubation.

    Measured: 15 minutes

  2. Overall number of intubation attempts

    Overall number of intubation attempts

    Measured: 15 minutes

  3. First attempt success rate of tracheal intubation

    First attempt success rate of tracheal intubation

    Measured: 15 Minutes

  4. Time required for intubation

    Time required for intubation (in seconds, defined from the first introduction of laryngoscope between the lips till successful lung ventilation defined as positive capnography)

    Measured: 5 minutes

  5. First EtCO2 after successful intubation

    Value in mmHg or kPa of the first reliable etCO2 reading after successful intubation

    Measured: 10 minutes

  6. Cormack-Lehane score

    Cormack-Lehane score at any attempt of laryngoscopy

    Measured: 5 minutes

  7. The need for additional devices

    The need for additional devices used at any step of intubation

    Measured: 5 minutes

  8. Respiratory complications

    Respiratory complications or complications of airway management within the first 24 hours, such as airway injury, cardiopulmonary resuscitation, bleeding, aspiration of gastric contents, post-extubation stridor, laryngospasm, bronchospasm, need for High Flow Nasal Oxygen (if not preoperatively on oxygen), need for low flow nasal oxygen (if not preoperatively on oxygen) or need for re-intubation will be recorded. Respiratory complications are defined as the need for re-intubation after being extubated, persistent stridor (even if oxygen is not required), respiratory failure, the occurrence of pneumothorax or the need for any additional diagnostic examination following respiratory problems (i.e., bronchoscopy, radiology).

    Measured: 24 hours

  9. Duration of severe desaturation

    Duration of moderate and severe desaturation (SpO2 < 80%), with or without bradycardia, during intubation.

    Measured: 15 minutes

  10. Percentage of Glottic Opening (POGO) score

    Percentage of Glottic Opening (POGO) score at any attempt of laryngoscopy, (0-100%). 100% best glottic opening

    Measured: 5 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Aug 2023
  2. Study start1 Dec 2023
  3. Primary completionJun 2027 (estimated)
  4. Study completionSep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
1,192 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05967507
Sponsor's protocol ID
OPTIMISE-2-trial
Acronym
OPTIMISE-2
Status last verified
May 2026
First submitted
19 Jul 2023
Last updated
12 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope and High-flow nasal supplemental oxygen (Fisher & Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope in people with Airway Management, run by Thomas Riva at 11 sites in 7 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 12 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 11 sites in Switzerland, Canada, United States, Australia, Brazil and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Alexander Fuchs, MD (+41 31 632 52 01, alexander.fuchs@insel.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

First attempt success rate (time frame: 15 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in